Medivation Announces Change in Executive Management Team

SAN FRANCISCO, CA--(Marketwired - Jul 10, 2014) - Medivation, Inc. (NASDAQ: MDVN) today announced Dawn Svoronos (formerly Graham) has been appointed as its chief commercial officer, reporting to David Hung, M.D., founder, chief executive officer and president of Medivation. Ms. Svoronos currently is a member of Medivation's Board of Directors and is a former president of Europe and Canada for Merck & Co. Inc, where she oversaw commercial operations in approximately 30 EU and EU accession countries. Ms. Svoronos will lead Medivation's commercial organization on an interim basis and will participate in the Company's search for a permanent chief commercial officer. Cheryl Cohen, Medivation's former chief commercial officer, has left the Company to pursue other opportunities.

"We thank Cheryl for her years of service to Medivation and wish her the best," said David Hung, M.D., president and chief executive officer of Medivation, Inc. "We are fortunate to have Dawn Svoronos, a seasoned executive with significant commercial expertise, step in on an interim basis to lead Medivation's commercial operations."

Ms. Svoronos, who was elected to Medivation's Board of Directors in April 2013, has more than 30 years of pharmaceutical industry experience spanning the U.S., Europe, Asia and Canada. In March 2011, Ms. Svoronos retired from Merck & Co., Inc, one of the world's leading healthcare companies, where she worked in the commercial side of the organization for 23 years. Ms. Svoronos is a former President of Europe and Canada for Merck. Before moving to Europe, Ms. Svoronos was President of Merck in Canada and prior to that, she was Vice President of Merck for Asia Pacific where she focused on advancing the commercial interests of Merck in Japan, China, and several other countries in Southeast Asia.

Medivation currently markets XTANDI^® (enzalutamide) capsules with its collaboration partner Astellas Pharma, Inc. XTANDI is currently approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have previously received docetaxel chemotherapy. In March 2014, Astellas and Medivation submitted a supplemental New Drug Application (sNDA) to the FDA seeking approval of XTANDI for the treatment of men with metastatic prostate cancer that has progressed on LHRH therapy or after bilateral orchiectomy. In May 2014, the FDA granted the sNDA application Priority Review designation with a Prescription Drug User Fee Act date of September 18, 2014.